GSK terminates its Alector pact after back-to-back Phase 2/3 flops in dementia and Alzheimer's, leaving Alector's pipeline preclinical-only.
July 9, 2026 06:51 AM EDT
DealsPharma
GSK walks away from Alector pact as immuno-neurology bet fizzles
Ayisha Sharma
News Reporter
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration…
Merck ends a Phase 2 Alzheimer's trial for MK-1167, partnered with Neuphoria Therapeutics, after the drug missed efficacy…
Pfizer's sigvotatug vedotin fails Phase 3 lung cancer trial, the third Seagen-acquired ADC to disappoint in roughly a year.
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
GSK ends brain drug alliance with Alector
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK (NYSE:GSK)
Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial
GSK, Hansoh ADC extends survival in lung cancer study
AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction
